<DOC>
	<DOC>NCT01467141</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to evaluate safety and efficacy in children with type 1 diabetes.</brief_summary>
	<brief_title>Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 1 diabetes Treatment with insulin for at least 6 months prior to inclusion HbA1c below or equal to 11.0 % Currently treated with short acting, intermediate acting, long acting human insulin or analogues or a selfmix of these insulins at least 1 month prior to inclusion The receipt of any investigational drug within one month prior to this trial Recurrent severe hypoglycaemia or hypoglycaemic awareness as judged by the investigator Total daily insulin doses at least 1.80 IU/kg Treatment with oral hypoglycaemic agents Known or suspected allergy to trial product or related products</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>